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Lithium-induced ADH resistance in toad urinary bladders
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and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Lithium-induced ADH resistance in toad urinary bladders. The
toad urinary bladder was used to investigate the site of action,
the underlying mechanism, and the means for production or
prevention of lithium-induced nephrogenic diabetes insipidus.
Short-circuit current (I) was used to measure net sodium trans-
port in paired quarter-bladders. Osmotic water flow (W) was
measured both volumetrically and gravimetrically. Mucosal
[Li at 11 mEq/liter produced inhibition of baseline I and both
ADH-induced cAMP-mediated I and W. However, lithium did
not inhibit propionate-induced I, or either dibutyryl cAMP-
induced I or W, confirming that lithium acts primarily by in-
hibition of ADH-induced, cAMP-mediated responses. Serosal
lithium had no effect at these concentrations. Either amiloride
(10—6 at) or triamterene (10 M) prevented all lithium inhibition,
proving that lithium acts from the mucosal surface. Increased
urinary [K or [H ] prevented lithium inhibition of ADH-
induced responses, suggesting that urinary composition may
be important in both production and prevention of lithium-
induced nephrogenic diabetes insipidus.
Résistance a l'ADH induite par le lithium dans les vessies
urinaires de crapauds. La vessie urinaire de crapaud a étó uti-
lisée pour étudier le site d'action, les mécanismes intimes et les
moyens de produire ou de prévenir le diabéte insipide néphro-
génique induit par le lithium. Le courant de court-circuit (I) a
été utilisé pour mesurer le transport net de sodium par des
quarts de vessie appariés. Le flux osmotique d'eau (W) a été
mesuré a la fois par volumetric et gravimétrie. Une concentration
de Li de 11 mEq/l a Ia face muqueuse a produit une inhibition
de la valeur basale de I et de l'action de l'ADH, médiée par la
cAMP, sur I et W. Le lithium n'a inhibé, cependant, ni l'action
du propionate sur I ni celle de dibutyril cAMP sur I et sur W,
ce qui confirme que le lithium agit principalement par l'inhibition
des réponses induites par l'ADH, médiées par cAMP. Ces con-
centrations de lithium Ia face séreuse n'ont pas eu d'effet.
L'amiloride (10—6 at) ou Ic triamterene (10 M) ont empêché
toute l'inhibition par le lithium, ce qui indique que le lithium
agit a partir de Ia face muqueuse. L'augmentation des concentra-
tions urinaires de K + ou de H + ont empéché l'inhibition par
le litijium des réponses a l'ADH, ce qui suggére que la composi-
tion de l'urine peut étre importante a Ia fois pour l'établissement
et la prevention du diabéte insipide néphrogénique induit par le
lithium.
Patients treated with lithium salts for manic-depressive
disorders frequently develop renal concentrating defects
and occasionally manifest frank diabetes insipidus [1—5].
Several studies have suggested that this defect is at least
partly "nephrogenic," i.e., that patients or animals with
such defects fail to respond appropriately to exogenous
antidiuretic hormone (ADH) [2—8]. These findings have
been confirmed in patients studied in detail in this labora-
tory [81; analysis of urinary concentrating ability and free
water clearance failed to detect any gross abnormalities in
sodium transport, and the anticipated resistance to exo-
genous ADH was present.
In addition, the mechanism of ADH-resistance was
studied in toad urinary bladders [8], a model similar to the
mammalian distal tubule [9]. This in vitro model of lithium-
induced nephrogenic diabetes insipidus was found to be
very sensitive to lithium inhibition within the range of
concentrations encountered clinically; very low con-
centrations of mucosal lithium (1.0 mEq/liter) produced
significant inhibition of baseline short-circuit current and
moderate concentrations (11 mEq/liter) inhibited vaso-
pressin-induced current and water flow. However, di-
butyryl cyclic adenosine 3',5'-monophosphate (cAMP)-
induced current and water flow responses were normal.
These observations suggested that lithium acts from the
urinary surface to block ADH activation of adenyl cyclase
to produce cAMP. The present study was designed primarily
to clarify the site and mechanism of action of lithium in
toad urinary bladders, and also to establish some of those
variables which may produce or prevent lithium inhibition.
For these purposes, the effects of amiloride, triamterenc,
Nat K, Ht and Mg + were studied on Li inhibition of
baseline, ADH-induced and propionate-induced transport.
A preliminary report of some of these findings has been
presented elsewhere [10].
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Methods
Urinary bladders were excised from doubly-pithed
female toads, Bufo marinus, obtained from the Dominican
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Republic (National Reagents, Bridgeport, Conn.). The
excised hemibladders were placed in continuously aerated
NaC1-Ringer's solution at room temperature (22 to 24° C)
for varying times prior to use. NaC1-Ringer's solution
contained: NaC1, 104.1 mM; KC1, 3.6 mM; CaC12, 0.7 mM;
and Na2HPO4, 0.7 mM; pH, 7.8 to 8.2; osmolality,
220 mOsm/kg H20. Lithium and choline Ringer's solutions
were made by isotonic, isohydric substitution for sodium,
as appropriate to the experimental conditions. Choline
chloride, ChC1, was obtained from Eastman Organic
Chemicals, Rochester, N.Y.; sodium propionate, NaPr,
was obtained from Sigma Chemical Co., St. Louis, Mo.
A double chamber similar to those described by Sharp
and Leaf [111, and based on the techniques of Ussing and
Zerahn [121, was used to study transepithelial potential
difference and short-circuit current. In all chamber experi-
ments, the hemibladders were mounted across the entire
chamber, so that each half of a single hemibladder isolated
its own serosal and mucosal compartments (cross-sectional
areas of 2.3 cm2). In this manner, a single hemibladder
provides an experimental and a control quarter-bladder.
The transepithelial potential difference (V) and the short-
circuit current (I) across each quarter-bladder were meas-
ured intermittently by methods described previously [13],
using Keithley 200 B Electrometers and a Weston 622
Microammeter, respectively. In all cases V and I were
followed until a stable baseline was obtained for at least
20 mm before any experimental manipulations. V, I and
water flow were usually determined at intervals of 5 mm
or less. Bladders with baseline V<lOmv, or resistance
<700 ohms were discarded in all experiments.
A double chamber with closed mucosal compartments
and horizontally mounted pipettes, similar to that described
previously [13], was used for simultaneous measurements
of electrical properties and water flow (compartment cross-
sectional areas of 2.0 cm2). (The current measurements
with an osmotic gradient were only used to document the
presence of lithium inhibition and to monitor bladder
viability in these water flow studies. Although the qualitative
current results with a gradient were similar to those
obtained without a gradient, all of the results report data
obtained without a gradient.) Paired quarter-bladder
experiments with either control water flow rate greater
than 2.0 uI/mm, or whose control quarter-bladder failed to
respond to vasopressin (at least five-fold increase in water
flow rate) were not used. The mucosal compartments
contained the appropriate Ringer's solution diluted in half
with distilled water to provide the osmotic gradient.
Solutions in each compartment (volume, 5.0 ml) were
changed by draining and refilling with the next solution.
(Pipette studies are reported in Table 2, section 4 only.)
Osmotic water flow was measured also in paired hemi-
bladders mounted on glass tubes ("bags") as described
by Bentley [14]. The appropriate Ringer's solution was
diluted in half with distilled water, and placed inside each
hemibladder to bathe the mucosal surface (volume, 5.0 ml);
the serosal surface of each hemibladder was bathed in
isotonic NaC1-Ringer's solution. Weight loss was measured
at 10 mm intervals for at least 30 mm before and after
vasopressin was added. Paired hemibladder experiments
whose control hemibladder failed to respond to vaso-
pressin (see above) were not used.
After a stable baseline was obtained in both chamber
(quarter-bladder) and bag (hemibladder) experiments,
either vasopressin (Pitressin®, Parke, Davis and Co.,
Detroit, Michigan), or dibutyryl-3',5'-cyclic adenosine
monophosphate (cAMP) (Schwarz BioResearch, Orange-
burg, N. Y.) was added to the serosal medium (final con-
centration: 100 mU/ml for vasopressin (ADH); 1.0 m for
cAMP), and the peak-induced water flow rate was deter-
mined within 40 mm. For the drug studies: amiloride
(courtesy of Dr. W. H. Wilkinson; Merck, Sharp and
Dohme, West Point, Pa.) was used at a final concentration
of 10 M mucosal medium; triamterene (courtesy of
Dr. B. Walker, Smith, Kline and French Laboratories,
Philadelphia, Pa.) was used at a final concentration of
10 s serosal medium.
Results
Site and mechanism of lithium inhibition
General characteristics. Previous studies from this
laboratory [8] and others [7] have shown that substitution
of Li+ for increasing fractions of the mucosal Na+ resulted
in significant decreases in transepithelial short-circuit
current. At mucosal [Li ] of 11 mEq/liter both baseline I
and the stimulation of I by subsequent addition of ADH
were significantly inhibited; although there were no
significant effects on baseline osmotic water flow (W),
ADH-induced W was also significantly inhibited. Therefore,
in the present experiments, unless otherwise indicated,
mucosal [Lit] = 11 mEq/liter. Li substitution in experi-
mental quarter-bladders was compared to control quarter-
bladders with choline, Ch, replacing the same fraction
of the mucosal Na+; thus both experimental and control
quarter-bladders had the same [Na J and ionic strength.
Since Li is both accumulated and transported by toad
urinary bladders [15], and since these [Ch] do not ap-
preciably affect I [8, 16], Li inhibition is likely to be
underestimated to the extent that lithium is itself trans-
ported [8].
A typical protocol consisted of the following:
Period 1 2 3
experimental quarter-bladder
control quarter-bladder (C)
(E) Na +
Na +
Li +
Ch +
ADH
ADH
Period 1 represents stabilization in the usual NaC1-Ringer's
solution (20 to 30 mm). Period 2 begins with replacement
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of the mucosal medium with LiC1-Ringer's (experimental)
or ChC1-Ringer's (control) solutions (see Methods), and
is of at least 20 mm duration. Period 3 begins with the
addition of ADH to the serosal medium and lasts until the
peak ADH effect is observed.
The differences between the experimental and control
quarter-bladders, (E—C), were compared in each period.
Although the mean baseline values were nearly always the
same in Period 1, individual variability could be corrected
for by normalizing for the initial values. Therefore, the
changes in baseline I for each quarter-bladder were also
evaluated by dividing the value for I in Period 2 by the
corresponding value in Period 1; the effect of Li was
compared to Ch by taking the ratio of the experimental
value to the control value (E/C), and expressing the result
as a percent of the control (%). Formally, if the period 1,
2 and 3 values for the experimental (inhibited) quarter-
bladder are a, b and c, and the corresponding values for the
control quarter-bladder are d, e and f, then: baseline
E/C(%)= 100 (Jd) —1 . In a similar manner, ADH-
induced E/C(%)= 100 [--
—ii. In water flow experi-
ments with paired hemibladders (bags) it was desirable to
avoid frequent alterations of the mucosal medium to
prevent mechanical injury; since Li+ had no effect on
baseline water flow in previous experiments [8], Period I
was omitted, and the initial media for the mucosal medium
contained Li+ (experimental) or Ch+ (control) as in
Period 2; the calculations were performed in a similar
manner to those for current.
The inhibitory effects of Li on baseline current, ADH-
induced current, and ADH-induced water flow, which were
observed in previous experiments [8], were reproduced in
the present series of experiments; a typical paired quarter-
bladder current experiment is shown in Fig. 1. For the
nine paired quarter-bladder current experiments, the mean
current in Period 1 was 54.3± SEM 10.8 ptA; there was no
significant difference between the experimental and control
groups. Themeanvalues ( 5EM) for Periods 2 (before ADH)
and 3 (after ADH), for both the current and water flow experi-
ments, are summarized in Table 1, top. The effects of Li + or
Ch+ are presented in absolute values (iA for current experi-
ments; lil/min for water flow experiments). The absolute
differences (ptA, or il/min) between the experimental and
control groups, i(E— C), are indicated with the significance
of each difference (Student's t test) given by the P value
beneath. The effects of ADH are presented as the ratio
of the absolute values in Period 3 to those in Period 2.
The E/C (%) values represent data normalized for the
preceding period (in this case, Period 1 with Nat), and
are calculated as described previously. N represents the
number of experiments of each type carried to that point
in the protocol.
All of the results in the following sections were obtained
with the indicated modifications of the basic protocol
Time, mm
Fig. 1. Inhibition of baseline and ADH-induced current by
lithium. Short-circuit current (I, 1iA) is indicated on the ordinate
for the experimental (Exp, open symbols) and control (Con,
solid symbols) quarter bladders. Time (mm) is indicated on the
abscissa. The first vertical dashed line indicates the time when
baseline NaC1-Ringer's solution was drained from the mucosal
compartments and replaced with either Lid-Ringer's (Exp)
or ChC1-Ringer's (Con) solutions. The second vertical dashed
line refers to addition of ADH to the serosal medium for both
quarter-bladders. Short-circuit current is significantly iithibited
by mucosal [Li + I of 11 mEq/liter, before and after addition of
ADH (see Table 1).
described above. The calculations were performed and
tabulated in an analogous manner, and will be compared
with those in Table 1 as appropriate.
Amiloride. The effects of amiloride on lithium inhibition
were studied because amiloride has been thought to block
mucosal cation entry specifically [17—19. The effects of
amiloride (Ami) on lithium inhibition of 1 were studied in
nine paired quarter-bladder experiments, according to the
protocol illustrated below:
Period I lA 2A 3A
experimental quarter-bladder (E) Na + Ami Li + ADH
control quarter-bladder (C) Na + Ami Ch + ADH
After stabilization in NaCI -Ringer's solution (Period 1, 20 to
30 mm), the mean short-circuit current for the 16 quarter-
bladders was 22.4± SEM 3.2 iA, with no difference between
experimental and control groups (A=2.3± SEM 2.8 jiA;
N— 8). Amiloride was then added to the mucosal medium
for each quarter-bladder (final concentration= l0 M),
and the full amiloride effect was allowed to develop
(Period 1 A; 20 mm). Amiloride produced a sharp decrease
in I (mean decrease = — 16.5± SEM 2.3 pA; N= 16;
P<0.OOl); the experimental and control groups behaved
in the same manner (A=1.8± SEM 1.0 pA; N=8; NS). The
results are summarized in Table 1 (center); the expected
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70
60
I.'
0
LI
20
10
0—
Lithium inhibition
• Con (Ch)
Exp (Li)
Lithium
Period
Baseline
Period Period
II I
10 20 30 40 50 60 70
154 Singer/Franko
Table 1. Effects of amiloride and triamterene on lithium inhibition
Mucosal
[Li ] =11 mEq/liter
Period 2 (
Current
flA
before ADH)
Water flow
p1/mm
Period 3 (after ADH)
Current Water flow
(ADH/Li + or Ch) (ADH/Li + or Ch)
N=9 N=20 N=9 N=9
Exp(Li) 15.4± 3.1 2.0±0.2 2.39± 0.31 16.2± 3.3
Con(Ch) 28.2± 4.2 1.7±0.2 3.52± 0.36 35.0± 7.8
A
—12.8± 2.7a 0.3±0.2
E/C (%) —52.0± 4.1 —28.1 10.0' —46.1 95a
Period 2A (before ADH) Period 3A (after ADH)
Amiloride N=8 N= 18 N=8 N=8
Exp(L11+Ami) 6.3± 1.4 0.9±0.2 2.44± 0.18 45.1±20.0
Con(Ch+Ami) 6.5± 1.2 0.9±0.2 1.97± 0.15 45.8± 9.1
A
—0.2± 0.6 0.0±0.3
E/C(%) —24.2±16.3 17.9 5.3 28.5±22.3
Triamterene N= 7 N= 14 N= 7 N= 8
Exp(Li*+Tri) 8.1± 1.2 1.2±0.3 4.64± 0.42 28.3± 8.3
Con(Ch+Tri) 8.0± 0.7 1.7±0.3 5.23± 1.00 25.6± 0.6
A 0.1± 1.2 —0.5±0.3
E/C(%) —5.4± 7.9 —1.4 11.5 6.8± 17.5
a P<0.001.
b P<0.025.
effects of lithium on baseline current (Period 2A) and
ADH-induced current (Period 3 A) are abolished. (Note that
in this case the E/C [%] values for Period 2 A are normalized
for Period 1 A, with amiloride present.) Similar amiloride
experiments (N= 11), omitting Period 1 A, yielded the same
results.
The effects of amiloride on lithium inhibition of W were
studied with a similar protocol, omitting Periods 1 and 1 A
as described earlier, and are summarized in Table 1, center.
There was no significant difference in baseline W (Period
2A) between the experimental and control groups, and the
expected inhibitory effect of lithium on ADH-induced
water flow was abolished (Period 3 A).
Triamterene. Recently it has been suggested that
amiloride might not only block mucosal cation entry, but
may also have effects on serosal cation exit; however,
triamterene did have a specific blocking action at the
mucosal surface [20]. Therefore, the effects of triamterene
(final concentration, 106 M) were studied in the same
manner as those of amiloride, except that the triamterene
was added to the serosal medium in Periods 1 A, 2 A and
3 A. The mean short-circuit current for the 14 quarter-
bladders in Period 1 was 15.4± SEM 2.1 iA, with no
difference between the experimental and control groups
(A=l.9± SEM 1.9 ptA; N=7). After triamterene addition,
the mean decrease in I was —3.4± SEM 1.4 tA; N= 14,
P<0.02), with no difference between the experimental and
control groups (A=1.l± SEM 1.4 iA; N=7). As in the case
of amiloride, the expected inhibitory effects of lithium on
baseline current, ADH-induced current and ADH-induced
water flow were prevented (Table 1, bottom). The effects
of lithium in the presence of amiloride and triamterene
should be compared and contrasted with the expected
effects of lithium alone. Since amiloride and triamterene
have a common action of blocking mucosal cation entry
[20], these results support the hypothesis that lithium acts
from the mucosal medium.
Serosal lithium and choline. A mucosal site of action was
proposed on the basis of marked mucosal-serosal differences
in sensitivity to lithium inhibition observed in previous
experiments [8]. On the other hand, Harris and Jenner [6]
have recently suggested that serosal lithium or choline
may inhibit ADH- or cAMP-induced W in Bentley bag
preparations. Since their study utilized a very different
experimental protocol, their derived data could not be
directly compared with our results. However, the potential
importance of their findings for understanding the site
and mechanism of lithium inhibition prompted more
rigorous and extensive studies of serosal lithium and
choline. The standard protocol described above was used
to study serosal lithium: water flow was measured by the
bag method in the cAMP studies, where cAMP replaced
ADH in period 3; water flow was measured by both the
pipette and bag methods in the ADH studies (the former
method is more specific but less sensitive). The standard
protocol was modified to study serosal choline only in
that choline replaced lithium as the experimental ion in
periods 2 and 3, and sodium was used as the control.
The water flow results are summarized in Table 2.
Neither ADH-induced nor cAMP-induced W were in-
hibited by serosal [Li ] at 11 mEq/liter when compared to
choline controls; ADH-induced W was not inhibited by a
serosal [Ch] of 11 mEq/liter when compared to sodium
controls. These data do not support a serosal site of
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Table 2. Effect of serosal lithium and choline on water flow
Period 2 (before ADH)
water flow (ui/mm)
pipettes bags
Period 3 (after ADH)
water flow (ADH/Li + or Ch )
pipettes bags
Serosal [Li ]= 11 mEq/liter
Exp (Lit)
Con (Ch)
A
E/C(%)
Serosal [Ch ] = 11 mEq/liter
Exp(Ch)
Con (Na
A
E/C(%)
Serosal [Li ]= 11 mEq/liter
Exp(Li)
Con (Ch )
A
E/C(%)
N= 8
0.6± 0.1
1.0±0.2
—0.4 0.2
Period 2
(before cAMP)
N= 10
0.9 0.1
0.9± 0.2
0.0± 0.2
N=7 N=8
15.2± 5.7 22.5± 4.9
16.6± 5.1 19.7± 3.9
—15.4± 17.2 10.6± 16.9
N= 8
67.7± 18.0
58.4 26.0
29.1 18.7
Period 3
(after cAMP)
N=9
28.7± 5.4
30.3± 8.6
—5.3 32.2
Period 2 Period 3
(before Pr) (after Pr)
Propionate Current
pA
Current
Pr/Lit or Ch -
Mucosal [Li + ]= 55 mEq/liter N= 7 N= 7
Exp(Li) 29.1± 10.4 1.73± 0.21
Con (Ch) 43.1± 13.8 2.33±0.33
A —14.0± 57
E/C (%) —28.9± 60b —21.4± 10.9
Mucosal [Li]= 11 mEq/liter N=9 N=9
Exp(Li) 32.2± 9.1 2.24± 0.33
Con (Ch) 49.1 12.4 1.97± 0.27
A
—16.9± 7.1k
E/C(%) —28.9± l1.4 14.5± 18.2
action for lithium, or suggest any inhibition of cAMP-
induced W by lithium. In contrast to the findings of
Harris and Jenner, the lack of any effect of serosal Ch+ or
Li + on ADH-induced W observed in the present study is
consistent with previous observations of others [7, 211.
Propionate. The effects of lithium on propionate-induced
short-circuit current were studied because propionate is
thought to stimulate sodium-transport by a mechanism
independent of, and additive with that of ADH [22, 23].
The same protocol as described above (General charac-
teristics) was used except that propionate (final concen-
tration of 0.1 M) was used instead of ADH in the serosal
medium. There was no significant difference between
experimental and control groups in Period I for any
Fig. 2. Relative inhibition of current. Inhibition (mean saM)
produced by lithium is presented as the ratio (E/C) of the ex-
perimental (Li ) to the control (Ch ) quarter-bladders, ex-
pressed as a per cent of the control; the dashed line at 100%
represents no difference between the paired experimental and
control quarter-bladders. Mucosal [Li ] of 11 mEq/liter pro-
duced significant inhibition of baseline (N= 29, P<0.00 1) and
ADH-induced (N= 9, P< 0.025) current; neither cAMP (N= 8)
nor propionate (Pr)-induced (N= 9) current were significantly
inhibited.
concentration of lithium employed: at [Li ]of 11 mEq/liter,
A=0.1± SEM 3.3 iA (N=9); at [Li] of 55 mEq/liter,
A= —0.4± SEM 3.7 iiA (N=7). The results from Periods 2
N=12 N=8
0.40 0.10
0.50± 0.14
—0.10± 0.07
1.1± 0.2
1.1 0.2
0.0± 0.2
Table 3. Effect of lithium on propionate-induced current I
a P<0.05.
b P<0.005.
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and 3 are summarized in Table 3. Propionate-induced I
was unaffected by Lit, although the usual inhibition of J
in Period 2 was observed. These results are compared with
those of Li on baseline, ADH-induced and cAMP-
induced current in Fig. 2. Although baseline I was in-
hibited, and although the concentrations of lithium used
were greater than those required to inhibit ADH-induced I,
propionate-induced I was not inhibited. Since propionate-
induced I is thought to be independent of ADH [22, 23],
and if cAMP-induced I is not affected by this {Li] [8],
the results suggest that Li + acts primarily to inhibit ADH
activation of adenyl cyclase to produce cAMP [8].
Prevention of lithium inhibition
Establishment of the probable mechanism and site of
Li + action permitted the study of some in vitro variables
which might also influence Li action.
Sodium. The effects of Na on Li inhibition of current
were studied by varying the [Lit] at the same Nat: Li
ratio. The basic protocol under "General characteristics"
was used, with the modified Ringer's solution in Periods 2
and 3; dilution with isotonic choline chloride provided the
alterations in concentration at the same Na+: Li+ ratio.
There were no significant differences between experimental
and control groups in Period 1 at any concentration or
ratio used. The results obtained with different [Lit] at a
Nat: Li ratio of 10: 1 are shown in Fig. 3. Although the
Nat: Li ratio is held constant at 10: 1, increasing [Lit]
produced successive inhibition of baseline I and ADH-
0
1.1 5.5 11 1.1 5.5 11 mEq[Li]
Baseline ADH-lnduced
current current
Fig. 3. Lithium inhibition at constant Na +: Li + ratio. The muco-
sal [Lit] is given on the abscissa for baseline current inhibition
(left) and for ADH-induced current inhibition (right); other
details as in Fig. 2. The P and N values for each [Li ] (mEq/liter)
are given below.
induced I. Similar results for baseline 1 were obtained at a
Nat: Li ratio of 99:1 ([Li1] of 1.1 and 0.55 mEq/liter);
ADH-induced I is unaffected by these [Lit]. Thus, the
[Lit], not the Nat: Li ratio, determines Li inhibition.
Table 4. Effects of increased [K ] or [H +1 on lithium inhibition
Mucosal
[L11]= 11 rnEq/liter
Period 2 (be
Current
1iA
fore ADH)
Water flow
ui/mm
Period 3 (aft
Current
ADH/Li or Ch
er ADH)
Water flow
ADH/Li or Ch
Potassium
[K]=10mEq/Iiter N=6 N=12 N=6 N=8
Exp (Li ) 34.2 11.3 1.9 0.5 3.85 0.65 29.2 10.7
Con(Ch) 38.0± 5.5 2.0±0.4 2.83± 0.23 26.8± 9.3
A
—3.8± 8.8
—0.2±0.6
E/C(%) —33.2± 43 29.9± 28.5 0.7± 11.2
Hydrogen
pH=6.4 N=7 N=14 N=7 N=7
Exp(Li) 21.0± 5.0 1.9±0.2 2.76± 0.58 15.1± 3.7
Con(Ch) 24.3± 6.6 1.3±0.3 2.49± 0.31 44.0± 10.2
A
—3.3± 2.6 0.6±0.4
E/C (%) —3.1 3.0 3.0 8.7 —55.2± ll.3'
pH=5.1 N=9 N=11 N=9 N7
Exp(Li) 17.6± 4.2 1.0±0.2 2.39± 0.22 22.2± 2.2
Con(Ch) 18.8± 5.5 1.3±0.2 2.34± 0.24 28.8±12.2
A
—1.2± 1.8 —0.3±0.2
E/C (%) 0.2± 4.2 3.0 2.6 5.7± 16.8
a P<0.O01.
b
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Magnesium: a) without lithium. Magnesium without
lithium (Group a) was compared to choline in seven
paired quarter-bladder experiments (for I) and ten paired
hemibladder experiments (for W). Whenever Mg+ + re-
placed a fraction of the mucosal Na+ for experimental
bladders, choline replaced the same fraction of the mu-
cosal Na for the controls; final [Mg ] of 10 mEq/liter.
There were no significant differences in I or W between
experimental and control groups for any period. Similar
results have been obtained by others [24, 25]. b) with
lithium. These experiments were repeated with [Lit] =
11 mEq/liter added to the mucosal medium. When com-
pared to Group (a), Group (b) showed the expected Li +
inhibition of ADH-induced W: with Mg (comparing
Group (a) with Group (b); N= 10), (b)/(a)= —33.0± SEM
14.2% (P<0.05); without Mg, (b)/(a)= —42.1± SEM
16.9% (P<0.05). However, there were no significant
differences between experimental (with Mg+ +) and control
(no Mg++) bladders, except in Period 3, where the com-
bination of Mg + and Li + produced slightly more inhibi-
tion of ADH-induced I than Li alone (EJC= —19.5± SCM
6.0%; P<0.02).
Potassium and pH. The effects of increased mucosal [K+]
or (H+] were studied by the same protocols, described under
"General characteristics", except that the mucosal [K]
was increased to 10 mEq/liter, or that the pH of the mucosal
medium was reduced to 6.4 or 5.1, as indicated, in each
period. There were no differences between experimental
and control quarter-bladders in Period 1; the results for
both I and W from Periods 2 and 3 are summarized in
Table 4. Lithium inhibition of ADH-induced responses is
abolished by increasing urinary [K ], although Li + in-
hibition of baseline I is still significant (see Table 1).
Lowering urinary pH to 6.4 abolishes the effect of Li +
baseline and ADH-induced I, but urinary pH must be
lowered to 5.1 to abolish Li inhibition of ADH-induced W
(see Table 1).
Discussion
The first objective of the present investigation was to
define the site and mechanism by which Li inhibits
ADH-induced I and W in toad urinary bladders. Since
both the mammalian renal medulla and the toad urinary
bladder respond to ADH by activation of adenyl cyclase
to produce cAMP as an intermediate for stimulation of
transport [9, 26—30], the site and mechanism of Li in-
hibition are likely to be the same in both tissues. The second
objective was to define some of the variables which could
enhance or prevent Li + inhibition in toad urinary bladders
(and possibly in patients).
Our previous studies suggested that Li blocks ADH-
activation of adenyl cyclase to produce cAMP because Li +
blocked ADH-induced I and W at concentrations which
did not affect cAMP-induced I and W [8]. Both the present
findings that Li does not affect ADH-independent,
propionate-induced I, and the recent reports that Li+
specifically inhibits ADH-activated adenyl cyclase in
mammalian renal medulla [31, 32], strongly support the
proposed mechanism for lithium-induced ADH resistance.
On the other hand, Forrest et al [4a, b] and Harris and
Jenner [6] demonstrated severely impaired ADH-respon-
siveness and somewhat less impaired cAMP-responsiveness
in Li + treated rats, which suggests that Li + may inhibit
both cAMP production and cAMP action. Harris and
Jenner [6] also studied the mechanism in toad urinary
bladders by the Bentley bag method [14], but their serosal
findings were not confirmed by Bentley and Wasserman [7]
using similar protocols or in the present study.
However, Bentley and Wasserman [7] were also unable
to confirm inhibition of ADH-induced W by mucosal
lithium [8]. The difference in results is probably due to our
use of peak water flow rate (measured at 10 mm intervals),
as opposed to their use of total water flow (for 30 mm
before and after ADH); at mucosal [Li ] of 11 mFq/liter,
their lithium inhibition just fails to achieve significance,
whereas when our data are recalculated in their manner,
the significance just disappears. Other differences include
their use of much lower doses of ADH, sodium-free
mucosal media and repeated use of the same hemibladders.
In any case, the fact that lithium can impair ADH-induced
W under any physiological circumstances may be more
pertinent than its inability to do so under others.
Bentley and Wasserman [7] have also studied the effects
of lithium on current in toad hemibladders. They con-
firmed that high mucosal or serosal [Lit] inhibit both
baseline I and ADH-induced I; low mucosal [Li ] were
not studied. However, they also demonstrated impaired
cAMP-induced I with much higher [Lit] and cAMP than
were employed in our previous study [8]. These results
imply that under some experimental conditions mucosal
Li can block the effects of cAMP. Since theophylline-
induced I was unaffected by Li [7], and if theophylline
exerts its action by increasing cAMP levels (by phospho-
diesterase inhibition), these data are also compatible with
Li + interfering with ADH activation of adenyl cyclase.
There is some evidence in humans [4b, 8] and animal
models [33] that Li could have a central action to stimulate
thirst or inhibit ADH release. Perhaps this is related to Li
inhibition of beta adrenergic hormone stimulation of
adenyl cyclase to produce cAMP in the hypothalamus
[33, 34]. Thus, Li not only blocks ADH activation of
adenyl cyclase to produce cAMP, but probably has addi-
tional actions to block the effect of cAMP on water flow
and to inhibit central ADH release.
The present investigation establishes that lithium exerts
its inhibitory action primarily from the mucosal (urinary)
surface. We have shown that while very low concentrations
are effective at the mucosal surface [8], only very high
concentrations of lithium are inhibitory at the serosal
surface [7, 8]. Neither ADH-induced nor cAMP-induced
water flow were inhibited by serosal lithium in the present
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study. The modest inhibition of I previously observed with
high serosal lithium concentrations was attributed to back
diffusion to the mucosal surface; perhaps the apparent
serosal site of action on water flow suggested by Harris
and Jenner [6] represents such back diffusion into a
mucosal medium of very low ionic strength. Since amiloride
[17—191 and triamterene [20] are thought to exert their
actions by specifically blocking mucosal cation entry,
abolition of lithium-induced ADH-unresponsiveness by
these drugs in the present study confirms that lithium acts
primarily from the mucosal (urinary) surface.
Since the defect a) depends on the [Lit] at the mucosal
(urinary) surface, b) results from blocking ADH and/or
cAMP action, and c) does not involve gross abnormalities
in sodium transport in humans, the site of the defect is
most likely in the distal nephron or collecting duct. These
characteristics of lithium inhibition suggest two general
ways to modify the distal renal actions of lithium without
loss of the therapeutic effects in the central nervous system:
1) decrease distal [Li ] by increasing urine volume or by
increasing proximal Li + reabsorption; 2) block distal Li +
uptake or action by ionic competition or by drug ad-
ministration.
Since lithium inhibition depends on the absolute urinary
[Li+] and since the syndrome itself predisposes to water
loss and dehydration, maintenance of adequate urine
volumes would help in prevention and treatment. The
alternative means of lowering distal [Li+] would be to
decrease distal delivery. Although Na depletion could
increase proximal reabsorption of both Na+ and Li+
[35—37], thereby reducing the distal [Lit] sufficiently to
prevent diabetes insipidus, such depletion can exaggerate
Li toxicity [33, 35—38].
Li+ incompletely competes with Na+ for transport
across the toad urinary bladder [15, 19, 20, 40]. However,
increasing the mucosal [Lit] from 11 to 55 mEq/liter does
not produce further inhibition of baseline I [8], and the
absolute [Lit], not the Nat: Li ratio, is critical for Li
inhibition. But these findings could also be explained by
competition: one possibility is that if only a fraction
(30 to 40%) of the Na + transport sites are Li + inhibitable,
Li + could then compete with Na + over the concentration
range up to [Li} of 11 mEq/liter, after which all of the
Li sensitive sites would be occupied and further inhibition
would not be expected; a second possibility is that if Li
is significantly transported across toad urinary bladder at
high concentrations [15], Li could then be substituted for
Na to maintain I and further inhibition of Na transport
would not be detected. Both proximal and distal effects
would have to be considered and the outcome at the site
of ADH-inhibition may not be easily predicted. The same
complex considerations apply to the possible use of the
distally-acting diuretics.
Although divalent cations often antagonize the effects
of univalent cations (e.g., [38, 39]), and although ADH-
sensitive adenyl cyclase from toad urinary bladder may
require Mg+ + as a co-factor [29], increasing mucosal Mg+ +
did not affect lithium inhibition of ADH-induced W.
The effects of increasing urinary [K} and lowering
urinary pH (below 7.8) were studied because H+ and K+
can compete with each other and with lithium both for
transport and accumulation by cells [15, 38, 42]. Increasing
urinary [K] did not abolish the inhibitory action of
lithium on baseline I, but both ADH responses were
unaffected by lithium when the urinary [K] was high:
At a urinary pH of 6.4, lithium failed to inhibit baseline
or ADH-induced I, and at a pH of 5.1, lithium inhibition
of ADH-induced W was also abolished. Since lithium may
also impair urinary acidification [43], an acidification
defect may contribute to subsequent development of
impaired concentrating ability. If confirmed, this impair-
ment would also preclude use of acidification to prevent
the diabetes insipidus.
The results of the present investigation suggest that
increasing urinary volume, [H +1 and [K+] are theoretical
ways of ameliorating the nephrogenic diabetes insipidus
syndrome in patients treated with lithium salts. In addition,
distally acting diuretics such as triamterene (and amiloride)
may be of therapeutic value, provided that effective levels
of lithium are maintained in the central nervous system;
the effects of diuretics and sodium are likely to be complex
in humans.
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